Objective: To systematically evaluate TCM of Fuzheng and Kangai combined with chemotherapy in the treatment of Advanced NSCLC, including the efficacy and effect on the quality of life of patients. Methods: Two researchers independently searched the literature of clinical trails from Jan.2010 until Jun.2020 in the Cochrane Library , Pubmed, Embase, CBM, CNKI, WanFang Data and VIP database. Also, they had been evaluated and extracted strictly by REVMAN 5.3. Results: A total of 1303 patients were included in 15 articles. The meta analysis shows that the TCM of Fuzheng and Kangai combined with chemotherapy can improve the objective response rate [OR=2.14,95％CI(1.67,2.74), P<0.00001], disease control rate [OR=2.54,95％CI(1.88,3.42), P<0.00001] and KPS score[OR=3.28,95％CI(1.92,5.60), P<0.0001], decrease the incidence rate of liver injury [OR=0.34,95％CI(0.21,0.54), P=0.003], hemoglobin reduction [OR=0.53,95％CI(0.28,1.01), P=0.05], leukopenia [OR=0.22,95％CI(0.13,0.39), P<0.00001], thrombocytopenia [OR=0.32,95％CI(0.21,0.50), P<0.00001] , toxic effects on the digestive systems [OR=0.30,95％CI(0.19,0.46), P<0.00001]. Conclusions: the experimental group was better than control one in short-term efficacy and KPS score. Furthermore, the experimental group can reduce the incidence rate of myelosuppression, toxicity of digestive system and liver.